Radiopharmaceuticals for PET and SPECT imaging: a literature review over the last decade
G Crișan, NS Moldovean-Cioroianu… - International journal of …, 2022 - mdpi.com
Positron emission tomography (PET) uses radioactive tracers and enables the functional
imaging of several metabolic processes, blood flow measurements, regional chemical …
imaging of several metabolic processes, blood flow measurements, regional chemical …
ImmunoPET: concept, design, and applications
W Wei, ZT Rosenkrans, J Liu, G Huang, QY Luo… - Chemical …, 2020 - ACS Publications
Immuno-positron emission tomography (immunoPET) is a paradigm-shifting molecular
imaging modality combining the superior targeting specificity of monoclonal antibody (mAb) …
imaging modality combining the superior targeting specificity of monoclonal antibody (mAb) …
Molecular and functional imaging in cancer-targeted therapy: current applications and future directions
JW Bai, SQ Qiu, GJ Zhang - Signal Transduction and Targeted Therapy, 2023 - nature.com
Targeted anticancer drugs block cancer cell growth by interfering with specific signaling
pathways vital to carcinogenesis and tumor growth rather than harming all rapidly dividing …
pathways vital to carcinogenesis and tumor growth rather than harming all rapidly dividing …
[HTML][HTML] A humanized antibody for imaging immune checkpoint ligand PD-L1 expression in tumors
S Chatterjee, WG Lesniak, M Gabrielson, A Lisok… - Oncotarget, 2016 - ncbi.nlm.nih.gov
Antibodies targeting the PD-1/PD-L1 immune checkpoint lead to tumor regression and
improved survival in several cancers. PD-L1 expression in tumors may be predictive of …
improved survival in several cancers. PD-L1 expression in tumors may be predictive of …
Current Perspectives on 89Zr-PET Imaging
JK Yoon, BN Park, EK Ryu, YS An, SJ Lee - International Journal of …, 2020 - mdpi.com
89Zr is an emerging radionuclide that plays an essential role in immuno-positron emission
tomography (PET) imaging. The long half-life of 89Zr (t1/2= 3.3 days) is favorable for …
tomography (PET) imaging. The long half-life of 89Zr (t1/2= 3.3 days) is favorable for …
The beginning of the end for conventional RECIST—novel therapies require novel imaging approaches
M Gerwing, K Herrmann, A Helfen… - Nature reviews Clinical …, 2019 - nature.com
Owing to improvements in our understanding of the biological principles of tumour initiation
and progression, a wide variety of novel targeted therapies have been developed …
and progression, a wide variety of novel targeted therapies have been developed …
Immuno-positron emission tomography with zirconium-89-labeled monoclonal antibodies in oncology: what can we learn from initial clinical trials?
YWS Jauw… - Frontiers in …, 2016 - frontiersin.org
Selection of the right drug for the right patient is a promising approach to increase clinical
benefit of targeted therapy with monoclonal antibodies (mAbs). Assessment of in vivo …
benefit of targeted therapy with monoclonal antibodies (mAbs). Assessment of in vivo …
ImmunoPET: antibody-based PET imaging in solid tumors
R Manafi-Farid, B Ataeinia, S Ranjbar… - Frontiers in …, 2022 - frontiersin.org
Immuno-positron emission tomography (immunoPET) is a molecular imaging modality
combining the high sensitivity of PET with the specific targeting ability of monoclonal …
combining the high sensitivity of PET with the specific targeting ability of monoclonal …
The role of 89Zr-immuno-PET in navigating and derisking the development of biopharmaceuticals
GAMS van Dongen, W Beaino… - Journal of Nuclear …, 2021 - Soc Nuclear Med
The identification of molecular drivers of disease and the compelling rise of biotherapeutics
have impacted clinical care but have also come with challenges. Such therapeutics include …
have impacted clinical care but have also come with challenges. Such therapeutics include …
Theranostics using antibodies and antibody-related therapeutics
KL Moek, D Giesen, IC Kok, DJA de Groot… - Journal of Nuclear …, 2017 - Soc Nuclear Med
In theranostics, radiolabeled compounds are used to determine a treatment strategy by
combining therapeutics and diagnostics in the same agent. Monoclonal antibodies (mAbs) …
combining therapeutics and diagnostics in the same agent. Monoclonal antibodies (mAbs) …